New York, NY -- (ReleaseWire) -- 04/15/2013 --Cytokinetics, Incorporated (NASDAQ: CYTK) and Families of Spinal Muscular Atrophy (FSMA) announced the award of a grant from FSMA to Cytokinetics to support preclinical research on muscle function in a mouse model of spinal muscular atrophy (SMA) to be conducted with the company`s fast skeletal muscle troponin activator, tirasemtiv. Financial details of the grant were not disclosed.
Tirasemtiv, the lead drug candidate from Cytokinetics` skeletal muscle contractility program, selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, thereby increasing skeletal muscle force in response to neuronal input and delaying the onset and reducing the degree of muscle fatigue.
Cytokinetics is evaluating tirasemtiv as a potential treatment for amyotrophic lateral sclerosis (ALS) in BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), an international Phase IIb clinical trial that is now enrolling patients.
Find out what momentum CYTK could adopt in the upcoming trading sessions here: http://stockreportdaily.com/market-scan/?symbol=CYTK
Array Biopharma Inc. (NASDAQ:ARRY) traded at $ 5.48 in the last session, which is +0.17 (3.20%). The stock has a Range of 5.25 - 5.54. The stock has a 52 week low and high of 3.00 - 6.17 respectively. The stock has a Market Cap of 639.30M. The stock traded a volume of 1.40M. The stock has a 30 day average volume of 969,246.00.
Analysts at Piper Jaffray upgraded shares of Array Biopharma Incorporated from a neutral rating to an overweight rating in a research note to investors on Monday, March 25th. They now have a $7.00 price target on the stock, up previously from $4.00.
Find out more on ARRY here:
Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Stockreportdaily.com
Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/
Stock Report Daily